Mainz Biomed (NASDAQ:QUCY) Posts Earnings Results

Mainz Biomed (NASDAQ:QUCY) released its quarterly earnings data on Tuesday. The company reported ($0.02) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.13 million during the quarter.

Mainz Biomed Trading Up 13.8%

Shares of QUCY stock opened at $0.47 on Wednesday. The company has a quick ratio of 0.43, a current ratio of 0.52 and a debt-to-equity ratio of 0.44. Mainz Biomed has a 52 week low of $0.40 and a 52 week high of $4.43.

Wall Street Analysts Forecast Growth

Several brokerages have commented on QUCY. Maxim Group lowered Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Weiss Ratings began coverage on Mainz Biomed in a research note on Thursday, March 12th. They issued a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Mainz Biomed currently has an average rating of “Reduce”.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.